[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604111":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":26,"locations":26,"responsibleParty":31,"collaborators":26,"id":35,"slug":26,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":40,"eligibilityCriteria":41,"healthyVolunteers":36,"sex":42,"minAge":43,"maxAge":44,"enrollmentInfo":45,"targetDuration":26,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":26,"overallStatus":55,"whyStopped":26,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":26},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"(control group)","PLACEBO_COMPARATOR","22 patients will continue their standard antiviral therapy (Entecavir 0.5 mg) for 6 months.",[13],"Drug: Entecavir (ETV)",{"label":15,"type":16,"description":17,"interventionNames":18},"(zinc group)","ACTIVE_COMPARATOR","22 patients will receive Zinc suIphate 220 mg orally once daily (equivalent to 50 mg elemental zinc), in addition to their standard antiviral therapy (Entecavir 0.5 mg), for 6 months.",[19],"Drug: Zinc (zinc sulphate)",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Entecavir (ETV)","Standard antiviral therapy with Entecavir 0.5 mg orally once daily for 6 months.\"(control group)",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Zinc (zinc sulphate)","Zinc sulfate 220 mg orally once daily (50 mg elemental zinc) in addition to Entecavir 0.5 mg, for 6 months.\"",[15],{"type":32,"investigatorFullName":33,"investigatorTitle":34,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Dina Ahmed Mohamed Ragai Elrefaey","clinical pharmacist","100604111",false,"NCT07145268","Zinc Sulphate in Treatment Fibrosis in HBV Patient Receiving Antiviral Therapy","Clinical Study to Evaluate the Possible Antifibrotic Effect of Zinc Sulphate in Chronic HBV Patient Receiving Anti Viral Therapy","HBV","Inclusion Criteria:\n\n* Patients with fibrosis stage (F2\\&F3) post chronic HBV infection receiving standard antiviral therapy.\n* Age \\> 18 and \\\u003C 65 years.\n\nExclusion Criteria:\n\n* Patients with prior history of liver transplantation.\n* Patients with prior history of hepatocellular carcinoma.\n* Patients coinfected with HIV or HCV.\n* Patients with any malignancies.\n* Pregnant and lactating women.","ALL","18 Years","65 Years",{"count":46,"type":47},44,"ESTIMATED","INTERVENTIONAL",[50],"PHASE2","This study aims to investigate the possible safety and efficacy of Zinc sulphate as antifibrotic agent in chronic HBV patient receiving antiviral therapy.",[53,54],"Liver Fibroses","HBV (Hepatitis B Virus)","NOT_YET_RECRUITING","2025-08-20",{"date":58,"type":59},"2025-08-28","ACTUAL",{"date":61,"type":47},"2025-09-01",{"date":63,"type":47},"2026-09",{"name":5,"class":6}]